Search our Database of Scientific Publications and Authors

I’m looking for a

    3612 results match your criteria Plaque Psoriasis

    1 OF 73

    Guselkumab for the Treatment of Psoriasis.
    BioDrugs 2018 Feb 22. Epub 2018 Feb 22.
    Department of Dermatology, Centro Hospitalar do Porto, Porto, Portugal.
    Psoriasis is a common, chronic, immune-mediated, inflammatory skin disease with systemic involvement and significant impact on patients' quality of life. Several biologic treatments have been developed in recent decades, such as tumor necrosis factor (TNF)-α inhibitors, a non-selective interleukin (IL)-23 inhibitor (ustekinumab, which also inhibits IL-12), and-most recently-IL-17 inhibitors. Guselkumab is a novel biological therapy that selectively targets IL-23 and is the first-in-class selective IL-23 inhibitor approved to treat moderate-to-severe plaque psoriasis. Read More

    Complete response of secukinumab in palmoplantar psoriasis.
    Dermatol Online J 2017 Oct 15;23(10). Epub 2017 Oct 15.
    Department of Dermatology, Hospital de Manacor, Islas Baleares, Spain. vrocamorad@
    Palmoplantar psoriasis is plaque psoriasis involving the palms and soles. Palmoplantar psoriasis is a treatment challenge for dermatologists and it is difficult to treat with topical and systemic therapies. Owing to its location and manifestations, palmoplantar psoriasis is associated with greater pain, functional limitations, and significant impairment of health-related quality of life. Read More

    Adalimumab-related alopecia in a patient affected by psoriasis.
    Dermatol Online J 2017 Jul 15;23(7). Epub 2017 Jul 15.
    Department of Dermatology, Hospital Universitari Sagrat Cor, Barcelona, Spain.
    Alopecia induced by biological therapy is a rare side effect of this type of drugs. A total of 23 patients of psoriasiform eruptions with severe scalp involvement that induced alopecia during anti-tumor necrosis factor (anti-TNF) treatment of non-dermatological conditions have been previously reported. We present a 50-year-old man affected by plaque psoriasis that developed psoriasiform patches with alopecia over his scalp 10 months after initiating treatment with adalimumab. Read More

    OBSERVE-5: Comparison of Etanercept-Treated Psoriasis Patients From Canada and the United States.
    J Cutan Med Surg 2018 Feb 1:1203475418755998. Epub 2018 Feb 1.
    6 Amgen Canada, Mississauga, ON, Canada.
    Background: OBSERVE-5 surveillance registry results evaluating etanercept safety and effectiveness in patients with moderate to severe psoriasis from Canada and the United States have been reported from data collected between May 2006 and December 2012. Although both countries have an identical indicated starting dose, the maintenance dose can differ and thus affect management strategies and outcomes.

    Objective: To compare the long-term safety and effectiveness outcomes of etanercept in the Canadian and US cohorts. Read More

    Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
    J Drugs Dermatol 2018 Feb;17(2):221-228

    BACKGROUND: Many patients with moderate plaque psoriasis are undertreated despite broadening treatment options. In the phase IV UNVEIL study, oral apremilast demonstrated efficacy and safety in systemic-naive patients with chronic moderate plaque psoriasis with lower psoriasis-involved body surface area (BSA; 5%-10%) during the 16-week, double-blind, placebo-controlled phase. We describe efficacy and safety of apremilast in this population through week 52 in UNVEIL. Read More

    Novel methotrexate soft nanocarrier/fractional erbium YAG laser combination for clinical treatment of plaque psoriasis.
    Artif Cells Nanomed Biotechnol 2018 Feb 15:1-7. Epub 2018 Feb 15.
    g Department of Pathology , National Research Centre, Cairo University , Cairo , Egypt.
    Psoriasis is a commonly encountered chronic dermatological disease, presenting with inflammatory symptoms in patients. Systemic treatment of psoriasis is associated with several adverse effects, therefore the development of a customized topical treatment modality for psoriasis would be an interesting alternative to systemic delivery. The therapeutic modality explored in this article was the comparative treatment of psoriatic patients using nanoparticulated methotrexate in the form of jojoba oil-based microemulsion with or without fractional erbium YAG laser. Read More

    Branch Duct-type Intraductal Papillary Mucinous Neoplasm Presenting as Paraneoplastic Small Plaque Para-psoriasis.
    Indian Dermatol Online J 2018 Jan-Feb;9(1):40-43
    Department of Pathology, VPS Lakeshore Hospital, Cochin, Kerala, India.
    To present and discuss a novel association between branch duct-type intraductal papillary mucinous neoplasm and paraneoplastic parapsoriasis. We present the case of a middle-aged male presenting with skin lesions that were suggestive of parapsoriasis, resistant to treatment, and in whom a diagnosis of branch-type intraductal papillary mucinous neoplasm of the pancreas was eventually made. A curative Whipple's surgery led to complete resolution of the skin lesions within 3 weeks. Read More

    Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors.
    Ann Rheum Dis 2018 Feb 9. Epub 2018 Feb 9.
    Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
    Objective: To determine whether tumour necrosis factor inhibitor (TNFi) use is associated with an increased rate of incident malignancy compared with no TNFi use in the treatment of juvenile idiopathic arthritis (JIA), paediatric inflammatory bowel disease (pIBD) and paediatric plaque psoriasis (pPsO).

    Methods: We performed a retrospective cohort study of administrative claims data from the USA from 2000 to 2014. Exposure to TNFi was considered permanent from the first observed exposure onward. Read More

    Comparative Effectiveness of Targeted Immunomodulators for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis.
    J Am Acad Dermatol 2018 Feb 10. Epub 2018 Feb 10.
    Division of General Internal Medicine and Geriatrics, Northwestern University Feinberg School of Medicine, Chicago, IL USA.
    Background: The comparative effectiveness of available targeted immunomodulators for moderate-to-severe psoriasis has not been evaluated.

    Objective: To evaluate the comparative effectiveness of targeted immunomodulators for adults with moderate-to-severe plaque psoriasis.

    Methods: Systematic literature review of placebo-controlled and head-to-head randomized trials of eight targeted immunomodulators that evaluated clinical benefits or harms. Read More

    Biologic Therapy In Psoriasis (Part I): Efficacy And Safety Of Tumor Necrosis Factor- Α Inhibitors.
    Curr Pharm Biotechnol 2018 Feb 9. Epub 2018 Feb 9.
    Dermatology Unit Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona. Italy.
    Background: Psoriasis is a chronic immune-mediated inflammatory disorder, with an estimated global prevalence of 2-3%. Psoriasis is associated with an impaired health-related quality of life and a substantial economic burden. Biologics, which target the pathways involved in the pathogenesis of psoriasis, represent an established therapeutic approach for moderate-to-severe plaque psoriasis, with remarkable efficacy and safety profile extensively examined and monitored. Read More

    Efficacy and safety of continuous every 2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase 3 trial (IXORA-P).
    Br J Dermatol 2018 Feb 6. Epub 2018 Feb 6.
    Eli Lilly and Company, Indianapolis, IN, USA.
    Introduction: Ixekizumab is an interleukin-17A antagonist approved for treatment of moderate-to-severe plaque psoriasis with recommended 160-mg starting dose, then 80 mg every 2 weeks (Q2W) through Week 12, and every 4 weeks (Q4W) thereafter. This study evaluated continuous every 2-week dosing (Q2W) over 52 weeks.

    Methods: In this Phase 3, multicentre, double-blinded, parallel-group trial, three ixekizumab dosing regimens were assessed for efficacy and safety at Week 52 in patients with moderate-to-severe plaque psoriasis randomized at a 2:1:1 ratio to continuous Q2W (N=611), continuous Q4W (N=310), or dose adjustment per protocol (Q4W/Q2W, N=306), each with a 160-mg starting dose. Read More

    Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies.
    Drugs Aging 2018 Feb;35(2):135-144
    Novartis Pharma GmbH, Nuremberg, Germany.
    Background: Psoriasis is a chronic inflammatory skin disease, affecting patients of a wide age range, including elderly patients. Elderly patients can respond differently to drug treatments and can be more vulnerable to adverse reactions. There are limited data on biologic therapies for psoriasis in elderly subjects. Read More

    Subcutaneous methotrexate in patients with moderate to severe psoriasis: a critical appraisal.
    Br J Dermatol 2018 Feb 5. Epub 2018 Feb 5.
    St John's Institute of Dermatology, King's College London and Guy's and St Thomas' NHS Foundation Trust, London, UK.
    Aim: Warren et alset out to assess the effect of an intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe chronic plaque psoriasis.

    Setting And Design: This is a prospective, double-blind, randomised (3:1), placebo-controlled study, conducted across 16 centres in Germany, France, the Netherlands, and the UK.

    Study Exposure: Methotrexate-naïve adults with a diagnosis of moderate to severe chronic plaque psoriasis for at least 6 months before baseline were randomly assigned to receive weekly subcutaneous injections of either methotrexate at a starting dose of 17. Read More

    Doppler versus Histopathology in the Assessment of Egyptian Patients with Psoriasis Treated with Acitretin.
    J Clin Aesthet Dermatol 2017 Nov 1;10(11):33-38. Epub 2017 Nov 1.
    Dr. M. Khater is Assistant Professor of Dermatology and Venereology.
    Psoriasis is one of the most common chronic inflammatory skin diseases, characterized by erythema and the formation of plaques. The diagnosis of psoriasis is based on clinical examination, and its severity is assessed by the Psoriasis Area and Severity Index. Histologic examination is still the standard method for the final diagnosis. Read More

    Treatment Satisfaction, Product Perception, and Quality of Life in Plaque Psoriasis Patients Using Betamethasone Dipropionate Spray 0.05.
    J Clin Aesthet Dermatol 2017 Nov 1;10(11):13-18. Epub 2017 Nov 1.
    Dr. Fowler is Co-Founder of Dermatology Specialists Research in Louisville, Kentucky, and Clinical Professor of Dermatology, University of Louisville School of Medicine, Louisville, Kentucky.
    To assess patient-reported satisfaction, efficacy, and tolerability associated with the use of betamethasone dipropionate spray 0.05% when applied twice daily in subjects with moderate plaque psoriasis.This was an open-label, multicenter study involving 45 patients with moderate plaque psoriasis, with the aim of evaluating patient-reported outcomes with betamethasone dipropionate spray 0. Read More

    Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab.
    Dermatol Ther (Heidelb) 2018 Mar 1;8(1):57-68. Epub 2018 Feb 1.
    Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
    Introduction: Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has been shown to have significant efficacy in the treatment of moderate to severe plaque psoriasis (PsO) and psoriatic arthritis (PsA), demonstrating a rapid onset of action and sustained responses with a favorable safety profile. All biotherapeutics, including monoclonal antibodies (mAbs), can be immunogenic, leading to formation of anti-drug antibodies (ADAs) that can result in loss of response and adverse events such as hypersensitivity reactions. Thus, the immunogenicity potential of biotherapeutics is of particular interest for physicians. Read More

    Real world data on the efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis.
    J Eur Acad Dermatol Venereol 2018 Feb 1. Epub 2018 Feb 1.
    A Sygros Hospital, 5 Ionos Dragoumi str, Rimini 1, Chaidari12462, Athens, Greece.
    Background: Psoriasis is a chronic inflammatory skin disease, which requires long term, safe and effective treatment. Apremilast, a small-molecule PDE4 inhibitor, has been introduced as psoriasis (and psoriatic arthritis) treatment in Europe in 2015.

    Objective: We analysed and report the efficacy and safety of apremilast in the first 51 patients with psoriasis that have undergone treatment with this novel small molecule in our outpatient clinic. Read More

    Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis.
    Psoriasis (Auckl) 2017 16;7:65-72. Epub 2017 Nov 16.
    Department of Dermatology, University of California, San Francisco, San Francisco, CA, USA.
    Psoriasis vulgaris is a chronic, immune-mediated systemic disease that affectŝ7.5 million people in the US. It can be treated with many therapies, often in combination, which include topicals, phototherapy, oral systemics, and biologics. Read More

    Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management.
    Psoriasis (Auckl) 2017 15;7:35-40. Epub 2017 Apr 15.
    Department of Dermatology, University of Rome Tor Vergata, Rome, Italy.
    The risk of hepatitis B virus (HBV) reactivation (HBVr) in chronic HBV carriers, in occult HBV patients or in acute HBV patients affected by psoriasis and treated with anti-tumor necrosis factor (TNF)-α agents is a clinical practice issue to face with, particularly if the treatment has a long-term maintenance finality. The aims of this review are to examine the current knowledge on HBVr incidence in chronic HBV carriers and potential occult carriers undergoing therapy with biologics for the treatment of psoriasis and psoriatic arthritis; analyze the prophylactic measure to prevent HBV reactivation and define how to manage HBVr in patients treated with biologics. We searched through PubMed, Google Scholar and Scopus databases and evaluated all published manuscripts concerning HBVr in psoriatic patients, both plaque-type and psoriatic arthritis, in treatment with any indicated anti-TNF-α. Read More

    Monitoring treatment response in psoriasis: current perspectives on the clinical utility of reflectance confocal microscopy.
    Psoriasis (Auckl) 2017 20;7:27-34. Epub 2017 Feb 20.
    Clinical Dermatology Department, San Gallicano Dermatological Institute, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.
    Reflectance confocal microscopy (RCM) evaluation of inflammatory skin diseases represents a relatively new technique that, during the past 5 years, has attracted increasing interest, with consequent progressive increment of publications in literature. The success of RCM is directly related to the high need for noninvasive techniques able to both reduce the number of skin biopsies and support clinical diagnosis and patient management. RCM helps to visualize microscopic descriptors of plaque psoriasis (PP) with good reproducibility between observers and a high grade of correspondence with histopathology. Read More

    Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis.
    Am J Clin Dermatol 2018 Jan 27. Epub 2018 Jan 27.
    AbbVie Inc., North Chicago, IL, USA.
    Background: Adalimumab is approved for the treatment of hidradenitis suppurativa (HS), plaque psoriasis, and other inflammatory conditions.

    Objective: Our objective was to examine the safety of adalimumab administered every other week (EOW) and every week (EW) in patients with HS and psoriasis and to investigate informative data from non-dermatologic indications.

    Methods: The safety of adalimumab 40-mg EOW versus EW dosing was examined during placebo-controlled and open-label study periods in patients with HS (three studies), psoriasis (two studies), Crohn's disease (six studies), ulcerative colitis (three studies), and rheumatoid arthritis (one study). Read More

    Efficacy and Safety of Apremilast Monotherapy for Moderate to Severe Psoriasis: Retrospective Study.
    J Cutan Med Surg 2018 Jan 1:1203475418755982. Epub 2018 Jan 1.
    4 Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada.
    Background: Apremilast is a new oral drug for the treatment of moderate to severe plaque psoriasis that reduces inflammation by inhibiting phosphodiesterase 4. Its efficacy and safety data are limited; hence, real-world outcomes are important for elucidating the full spectrum of its adverse events (AEs) and expanding generalizability of clinical trial findings.

    Objective: Assess the efficacy and safety of apremilast monotherapy in real-world practice. Read More

    Prevalence of Oral Mucosal Lesions and Their Association with Severity of Psoriasis among Psoriatic Patients Referred To Dermatology Clinic: A Cross-Sectional Study in Kashan/Iran.
    Open Access Maced J Med Sci 2017 Dec 24;5(7):978-982. Epub 2017 Oct 24.
    Kashan University of Medical Sciences, Kashan, Iran.
    Background: Psoriasis is a common inflammatory papulosquamous disease of the skin with unknown aetiology that may be associated with the abnormal T-cell function.

    Aim: This study was aimed to determine the prevalence of oral mucosal lesions and their associations with severity of psoriasis in psoriatic patients attending the dermatologic clinic of Shahid Beheshti Teaching Hospital at Kashan, Iran.

    Methods: In this cross-sectional descriptive analytic study, all consecutive patients with psoriasis who referred to the dermatologic clinic at the Shahid Beheshti Hospital of Kashan University of Medical Sciences in Kashan City/ Iran were enrolled. Read More

    The budget impact of brodalumab for the treatment of moderate-to-severe plaque psoriasis on US commercial health plans.
    J Med Econ 2018 Feb 2:1-5. Epub 2018 Feb 2.
    d Novosys Health , Green Brook , NJ , USA.
    Introduction: Brodalumab is a new biologic approved by the US Food and Drug Administration in 2017 for the treatment of moderate-severe psoriasis. This study evaluated the impact of the introduction of brodalumab on the pharmacy budget on US commercial health plans.

    Methods: An Excel-based health economic decision analytic model with a US health plan perspective was developed. Read More

    A multicenter, prospective, observational study examining the impact of risk factors, such as BMI and waist circumference, on quality of life improvement and clinical response in moderate-to-severe plaque-type psoriasis patients treated with infliximab in routine care settings of Greece.
    J Eur Acad Dermatol Venereol 2018 Jan 22. Epub 2018 Jan 22.
    1st Department of Dermatology, A. Syggros Hospital, University of Athens, Athens, Greece.
    Background: Obesity has been associated with moderate-to-severe plaque psoriasis severity and PASI 75 response attainment of biologic therapies, but findings are inconsistent.

    Objective: This study aimed to examine the association of body mass index (BMI) and waist circumference (WC) on disease severity, to identify potential patient characteristics associated with response attainment, and to assess the impact of infliximab on the patients' health-related quality of life (HRQoL) among infliximab-treated patients in the routine care setting of Greece.

    Methods: This was a multicenter, prospective, observational study of adult moderate-to-severe plaque psoriasis patients who had initiated treatment with originator infliximab within 2 weeks prior to enrollment. Read More

    Psoriasis: from Pathogenesis to Targeted Therapies.
    Clin Rev Allergy Immunol 2018 Feb;54(1):102-113
    Department of Dermatology, Lausanne University Hospital CHUV, Lausanne, Switzerland.
    Over the last decade, the management of psoriasis has witnessed a paradigm shift. Thanks to the increasing knowledge about the pathogenesis of psoriasis, targeted treatments with monoclonal antibodies have been developed. These antibodies, which target the pathogenic TNF/IL-23/IL-17-pathway, were shown to be safe and efficacious in the management of most patients with moderate to severe chronic plaque psoriasis. Read More

    Apremilast Use in a Case of Cicatricial Ectropion Secondary to Severe Lamellar Ichthyosis.
    Ophthal Plast Reconstr Surg 2018 01 17. Epub 2018 Jan 17.
    Department of Ophthalmology, School of Medicine, West Virginia University.
    Ichthyosis is a cutaneous disorder characterized by excessive amounts of dry thickened skin surface scales. Ocular manifestations of ichthyosis include cicatricial ectropion, which may cause exposure keratoconjunctivitis and rarely corneal perforation. Topical emollients, anti-inflammatory ointments, and systemic retinoids have been used to control the disease process, while surgical correction with donor graft has been reserved for severe cases involving corneal exposure. Read More

    Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis.
    Ther Adv Chronic Dis 2018 Jan 16;9(1):5-21. Epub 2017 Nov 16.
    Baylor Scott and White- Division of Dermatology, 3900 Junius Street, Suite 125, Dallas, TX 75246, USA.
    Psoriasis is a systemic inflammatory disease associated with numerous comorbidities and a profound impact on patients' quality of life. While its complex immune pathogenesis is still not fully delineated, current evidence supports a fundamental role of the T-helper-17 (TH-17) pathway and its related interleukin-17 (IL-17) cytokine. Thus, new antipsoriatic therapies have been developed to block this key cytokine and its downstream effects. Read More

    Carboxytherapy for treatment of localized chronic plaque psoriasis: Clinical and histopathologic evaluation.
    J Cosmet Dermatol 2018 Jan 17. Epub 2018 Jan 17.
    Dermatology and Venereology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
    Background: Multiple treatment options are introduced in treatment of chronic localized plaque psoriasis but with poor adherence and poor patients' satisfaction resulting in poor treatment outcome.

    Objective: In this pilot study, we investigated the safety and efficacy of carboxytherapy in treatment of chronic localized plaque psoriasis.

    Methods: Thirty adult patients with chronic localized plaque psoriasis were enrolled in this study. Read More

    Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1λ Monoclonal Antibody Targeting IL-23, in Patients with Moderate to Severe Plaque Psoriasis.
    J Clin Pharmacol 2018 Jan 17. Epub 2018 Jan 17.
    Global Clinical Pharmacology, Janssen Research & Development, LLC, Spring House, PA, USA.
    Psoriasis is a common inflammatory skin disorder that requires chronic treatment and is associated with multiple comorbidities. Guselkumab, a human immunoglobulin-G1-lambda monoclonal antibody, binds to interleukin-23 with high specificity and affinity and is effective in treating moderate to severe plaque psoriasis. As part of the guselkumab psoriasis clinical trial program, using a confirmatory approach, a population pharmacokinetics (PopPK) model was established using 13 014 PK samples from 1454 guselkumab-treated patients across 3 phase 2/3 trials. Read More

    A cost-effectiveness analysis of calcipotriol plus betamethasone dipropionate aerosol foam versus gel for the topical treatment of plaque psoriasis.
    Curr Med Res Opin 2018 Jan 24:1-7. Epub 2018 Jan 24.
    c LEO Pharma A/S , Ballerup , Denmark.
    Background: Calcipotriol 50 µg/g and betamethasone 0.5 mg/g dipropionate (Cal/BD) aerosol foam formulation provides greater effectiveness and improved patient preference compared with traditional Cal/BD formulations for the topical treatment of plaque psoriasis.

    Objective: To determine the cost-effectiveness of Cal/BD foam compared with Cal/BD gel from the Australian perspective. Read More

    Secukinumab in multi-failure psoriatic patients: the last hope?
    J Dermatolog Treat 2018 Jan 23:1-3. Epub 2018 Jan 23.
    a Department of Specialized , Diagnostic and Experimental Medicine University of Bologna , Italy.
    Psoriasis is a multi-systemic chronic inflammatory disease that affects about 1.5-3% of the general population, of which almost 20% suffer from a moderate-severe form. Those patients can be treated with a systemic agent and in case of scarce response or contraindications, they may require a biologic therapy, such as tumor necrosis factor or interleukin-12/23 inhibitors. Read More

    Evaluation of ICAM-1 expression and vascular changes in the skin of patients with plaque, pustular, and erythrodermic psoriasis.
    Int J Dermatol 2018 Feb 10;57(2):209-216. Epub 2018 Jan 10.
    Sector of Dermatology, Rio de Janeiro State University, Rio de Janeiro, Brazil.
    Background: Psoriasis is a chronic inflammatory disease. Pustular, erythrodermic, and extensive plaque psoriasis are responsible for systemic complications. Systemic capillary leak syndrome is the complication with greater progression to death and occurs due to vascular changes. Read More

    Efficacy and safety of switching to ixekizumab in secukinumab non-responders with plaque psoriasis: a multicenter retrospective study of interleukin (IL)-17A antagonist therapies.
    J Am Acad Dermatol 2018 Jan 4. Epub 2018 Jan 4.
    Faculty of Medicine, University of Toronto, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Women's College Hospital, Toronto, ON, Canada; Probity Medical Research Inc., Waterloo, ON, Canada. Electronic address:

    Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials.
    Value Health 2018 Jan 18;21(1):1-8. Epub 2017 Aug 18.
    Analysis Group Inc., Boston, MA, USA.
    Objectives: To compare outcomes between adalimumab and etanercept in the treatment of moderate to severe plaque psoriasis.

    Methods: Study groups included patients randomized to adalimumab or placebo (REVEAL and CHAMPION trials) and those randomized to etanercept or placebo (M10-114 and M10-315 trials). Week 12 outcomes were compared between patients receiving adalimumab and those receiving etanercept after adjusting for cross-trial differences in patient characteristics using propensity score weighting and after subtracting effects of placebo. Read More

    Contemporary management of moderate to severe plaque psoriasis.
    Am J Manag Care 2017 Dec;23(21 Suppl):S403-S416
    Department of Dermatology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA. Email:
    Psoriasis is a multisystem inflammatory disease that is often underdiagnosed, leaving many patients untreated. Plaque psoriasis, the most common form of the disease, affects approximately 80% to 90% of patients with psoriasis. Formulating a treatment plan can be complicated when various factors are considered. Read More

    Expression of Elafin in Dermatitis Herpetiformis.
    Am J Dermatopathol 2018 Jan;40(1):1-6
    Professor of Dermatology and Dermatopathology, Department of Dermatology, University of Miami, University of Florida, Nova Southeastern University, FL.
    Background: Elafin is a serine protease inhibitor that has various epithelial cell regulatory and immunomodulatory effects including inactivation of neutrophil elastases. This later role originated the interest of elafin in certain neutrophil-rich dermatoses. Interestingly, it has been speculated that elafin has a protective role by slowing the deamidation process of gliadin in celiac disease (CD), despite the typical absence of neutrophils in intestinal histologic samplings. Read More

    Double trouble: psoriasis and cardiometabolic disorders.
    Cardiovasc J Afr 2017 Dec 13;28:1-6. Epub 2017 Dec 13.
    Department of Internal Medicine, Chris Hani Baragwanath Academic Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
    Psoriasis (PsO) is a chronic immune-mediated inflammatory skin disorder associated with numerous co-morbidities. This descriptive review focuses on the cardiometabolic co-morbidities of PsO with reference to the epidemiology and pathogenetic mechanisms linking PsO and cardiometabolic disease (CMD). Registry-based studies have shown PsO to be associated with an increased risk of cardiovascular morbidity and mortality. Read More

    Management of Common Side Effects of Apremilast.
    J Cutan Med Surg 2017 Dec 1:1203475417748886. Epub 2017 Dec 1.
    1 The University of Ottawa, K19 4E9, Ottawa, ON, Canada.
    Apremilast is a relatively new therapy for the treatment of moderate to severe plaque psoriasis in adults. While this medication is considered safe with a very low risk of serious side effects, a few common (≥5% of patients) mild to moderate side effects have been reported, including diarrhea, nausea, headache, and nasopharyngitis. Not addressing these symptoms may lead to medication nonadherence and unnecessary discontinuation of therapy. Read More

    RNA-seq identifies a diminished differentiation gene signature in primary monolayer keratinocytes grown from lesional and uninvolved psoriatic skin.
    Sci Rep 2017 Dec 22;7(1):18045. Epub 2017 Dec 22.
    University of Michigan, Department of Dermatology, Ann Arbor, MI, 48109-2200, USA.
    Keratinocyte (KC) hyper-proliferation and epidermal thickening are characteristic features of psoriasis lesions, but the specific contributions of KCs to plaque formation are not fully understood. This study used RNA-seq to investigate the transcriptome of primary monolayer KC cultures grown from lesional (PP) and non-lesional (PN) biopsies of psoriasis patients and control subjects (NN). Whole skin biopsies from the same subjects were evaluated concurrently. Read More

    Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Cochrane Database Syst Rev 2017 12 22;12:CD011535. Epub 2017 Dec 22.
    Department of Dermatology, Hôpital Henri Mondor, 51 Avenue du Maréchal de Lattre de Tassigny, Créteil, France, 94000.
    Background: Psoriasis is an immune-mediated disease for which some people have a genetic predisposition. The condition manifests in inflammatory effects on either the skin or joints, or both, and it has a major impact on quality of life. Although there is currently no cure for psoriasis, various treatment strategies allow sustained control of disease signs and symptoms. Read More

    Safety and efficacy of etanercept monotherapy for moderate-to-severe plaque psoriasis: A prospective 12-week follow-up study.
    J Huazhong Univ Sci Technolog Med Sci 2017 Dec 21;37(6):943-947. Epub 2017 Dec 21.
    Department of Dermatology, Chinese PLA General Hospital, Medical College of Chinese PLA, Beijing, 100853, China.
    Etanercept has been shown to be effective for the treatment of moderate-to-severe plaque psoriasis. Since most clinical trials examined etanercept in combination with other drugs, the efficacy and safety of etanercept monotherapy for moderate-to-severe plaque psoriasis have not been well established. This prospective study enrolled 61 Chinese patients with moderate-to-severe plaque psoriasis to explore the efficacy and safety of etanercept monotherapy. Read More

    The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis.
    J Clin Pharmacol 2017 Dec 21. Epub 2017 Dec 21.
    Pfizer, Cambridge, MA, USA.
    The safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06700841 were assessed in a randomized, double-blind, placebo-controlled, single- and multiple-dose escalation, parallel-group study in healthy subjects and patients with plaque psoriasis. The single ascending dose (1, 3, 10, 30, 100, or 200 mg) and multiple ascending dose (MAD; PF-06700841; up to 175 mg once daily or 50 mg twice daily for 10 days) periods included 54 healthy participants. In addition, 30 patients with psoriasis received PF-06700841 30 or 100 mg or placebo once daily for 28 days. Read More

    Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: a case series.
    Br J Dermatol 2017 Dec 19. Epub 2017 Dec 19.
    National Taiwan University Hospital, Department of Dermatology, Taipei, Taiwan.
    Erythrodermic psoriasis (EP) is a rare but severe variant of psoriasis. Evidence-based treatment of EP is limited due to its rarity and lack of controlled studies. Secukinumab is an anti-IL17A monoclonal antibody approved for the treatment of moderate to severe psoriasis with superior efficacy compared to etanercept and ustekinumab. Read More

    Evaluation of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in Turkish patients with chronic plaque psoriasis.
    Acta Dermatovenerol Alp Pannonica Adriat 2017 Dec;26(4):97-100
    Department of Biochemistry, Faculty of Medicine, Abant İzzet Baysal University, Bolu, Turkey.
    Introduction: This study evaluates the relationship between disease activity and neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in patients with chronic plaque psoriasis.

    Methods: Clinical and biochemical data were retrieved through retrospective examination of patients' and healthy subjects' medical records. NLR and PLR values were calculated from the hemogram results. Read More

    Histopathological aspects of psoriasis and its uncommon variants.
    G Ital Dermatol Venereol 2017 Dec 15. Epub 2017 Dec 15.
    Section of Dermatology, Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy.
    Psoriasis is a chronic complex multisystem, inflammatory, skin disorder that causes vasodilatation and hyperproliferation of keratinocytes, whose clinical expression includes a thickened, erythematous skin, often covered with silver grey scales. Psoriasis is a unique disease where both autoimmune and autoinflammatory responses coexist and the balance between the two components is essential in determining its clinical and histopathological presentation. Adaptive immune responses prevail in chronic plaque psoriasis while innate and autoinflammatory responses predominate in pustular psoriasis. Read More

    1 OF 73